Oak Hill Bio
Private Company
Total funding raised: $57M
Overview
Oak Hill Bio is a UK-based biotech with a unique 'relay' business model, acquiring and advancing late-stage rare disease programs abandoned by larger pharmaceutical companies. Its lead assets are rugonersen (OHB-724), an ASO for Angelman syndrome entering Phase 3, and OHB-607, a recombinant protein for bronchopulmonary dysplasia prevention in preemies, currently in Phase 2b with partner Chiesi. The company operates with a lean, asset-centric approach, aiming to de-risk development and deliver first- or best-in-class therapies to underserved patient populations.
Technology Platform
Strategic model for acquiring and developing deprioritized late-stage rare disease therapeutics across modalities (ASO, recombinant protein, small molecule).
Funding History
2Opportunities
Risk Factors
Competitive Landscape
In Angelman syndrome, rugonersen is among the leading ASO candidates, but other modalities (gene therapy, gene editing) are in earlier development. For BPD, OHB-607 is a first-in-class approach, competing against supportive care and other investigational agents. The DME space is highly competitive with multiple approved anti-VEGF therapies, though OHB-401's novel mechanism could differentiate it.